Core Viewpoint - The company has received FDA approval for its biosimilar drug POHERDY® (HLX11), which is a significant milestone for its international market presence and product recognition [1][2][3] Group 1: FDA Approval - The FDA approved the biologics license application (BLA) for POHERDY® (HLX11) for intravenous use, with indications for treating HER2-positive metastatic breast cancer (MBC) in adults who have not previously received anti-HER2 treatment or chemotherapy [1] - The approval is based on comprehensive reviews of comparative studies demonstrating the similarity in quality, safety, and efficacy between HLX11 and its reference drug, Perjeta® [2] Group 2: Market Potential - HLX11 is projected to generate approximately $3.304 billion in global sales in 2024, indicating a strong market potential for the product [3] - Following the approval of POHERDY®, the company has a total of seven products approved for overseas markets, with four of those in the United States, enhancing its international market strategy [3] Group 3: Collaboration and Future Plans - The company has entered into an exclusive licensing agreement with Organon LLC for the commercialization of HLX11 outside of China and Hong Kong, Taiwan [3] - The company plans to advance local commercialization efforts in collaboration with Organon LLC once conditions are favorable [3]

Core Insights - EirGenix Inc. has entered into a second global exclusive licensing agreement with Sandoz AG for the commercialization of its breast cancer biosimilar EG1206A, covering all territories except specific Asian markets [1][2] - The agreement includes up to USD 152 million in upfront and milestone payments, along with profit sharing and sales incentives post-launch [1][2] - EG1206A has received positive feedback from the U.S. FDA and EMA, allowing for an abbreviated development pathway without Phase III trials [2] Company Developments - EirGenix has successfully developed multiple biosimilar products using reverse engineering technologies, enhancing its global competitiveness [5] - The company is accelerating the development of four HER2-targeted antibody programs and expanding its product pipeline and CDMO services [5] - EirGenix's production capacity and facilities have attracted attention from international pharmaceutical companies, indicating strong growth potential [5] Market Context - There are approximately 2.3 million breast cancer patients globally, with 20% diagnosed with HER2-positive disease, indicating a significant market for EG1206A [3] - The combination therapy of Trastuzumab and Pertuzumab is the current standard of care, with potential market expansion for EG1206A as new treatment options emerge [3] - Roche's Perjeta® generated global sales of approximately USD 4 billion in 2024, highlighting the lucrative market for HER2-targeted therapies [3][4] Strategic Partnership - The partnership with Sandoz strengthens the existing collaboration, following a previous agreement for EG12014, which is already approved in Europe and under review in the U.S. [2] - Sandoz is a leader in affordable medicines, with a portfolio of around 1,300 products and net sales of USD 10.4 billion in 2024 [4]